Anterior Lumbar Interbody Fusion (ALIF) is n operation performed from the front of the spine, where a damaged disc (or discs) is removed and replaced by a new plastic disc (cage filled with bone).
ALIF can treat various spinal conditions, including degenerative disc disease, spondylolisthesis (slippage of one vertebra over another), spinal instability, and certain spinal deformities.
Generally, ALIF is considered appropriate for individuals who:
However, the final decision about the suitability of ALIF is made individually after a thorough evaluation by a spine specialist, considering the patient's unique circumstances and medical history.
The benefits of Anterior Lumbar Interbody Fusion (ALIF) include:
Tell Mr Malham about any medical conditions or previous operations. Suppose you have a medical condition such as diabetes, heart problems, high blood pressure or asthma. In that case, Mr Malham may arrange for a specialist physician to see you for a pre-operative assessment and medical care following the neurosurgery.
Inform Mr Malham of the medication you are taking and/or have allergies to medications. You must stop using the following ten days pre-operatively:
You must stop using blood thinning medication (such as Warfarin) 3-5 days pre-operatively.
Pre-operative investigations may include:
A “Cell-Saver” machine is used to clean the recycled and any lost blood back to you during the operation.
Positioned supine in a lithotomy position.
Image intensifier identification and marking of disc level on the skin. Right lower transverse abdominal skin incision for L5/ S1 disc level, or vertical lower abdominal skin incision (midline) for L4/S disc level.
Opening of anterior and then posterior rectus sheath. The left rectus muscle is then retracted to the right. Dissection in retroperitoneal plain. Bowel moved to the right. Psoas muscle was identified. Left ureter protected and swept to the right. Identification of left common iliac artery, then underlying left common iliac vein.
To approach the L4/5 disc, dissection lateral to iliac vein identifying, ligating and then dividing ascending lumbar vein. This enables the iliac artery and vein to be moved to the right, exposing the L4/5 disc.
To approach L5/S1 disc, dissection medial to the iliac vein. The inferior hypogastric plexus is swept to the right, exposing the L5/S1 disc between the left and right iliac vein and artery.
Special retractors are then used to carefully hold “out of the way and protect” the bowel, ureter, iliac arteries and veins. These retractors are connected to a frame connected to the operating table.
A lateral image intensifier is used to confirm the disc level, and the AP image intensifier marks the midline.
Discectomy is performed, removing the entire damaged disc.
The posterior osteophytes (bony spurs) are removed.
The exiting nerve roots are decompressed.
The posterior longitudinal ligament may be opened.
The upper and lower vertebral endplates are cleaned of any soft tissue.
The trial implant enables the correct size “cage” implant to be chosen. The cage is trapezoid in shape and wider at the front than behind, restoring the normal lumbar curve or lordosis. The cage is made with ‘Space Age Plastic’, PEEK (Poly Ether Ether Ketone), with an attached titanium plate enabling three titanium screws to fix the cage to the above and below vertebrae. It is filled with bone morphogenic protein (Infuse, BMP-2) to avoid the need to harvest iliac crest (hip) bone graft. The cage is then impacted into the disc space, and the optimal position is confirmed with the image intensifier.
The retractor blades are then carefully removed. The bowel, iliac arteries and veins are inspected carefully to exclude damage.
The wound is closed in layers with suturing of the posterior and anterior rectus sheath, subcutaneous layers and dissolving sutures to the skin.
You are then woken from general anaesthesia, and the breathing tube is removed.
A CT Scan will be required on Day 2.
Generally, ALIF has a favourable prognosis, with 70 - 80% of patients reporting significantly improved pain, function and reduced analgesic requirements. 20% of patients will be the same after the operation, and approximately 5% will worsen with increased pain and reduced function.
The total risk of surgical complications is 3%. The medical risks of any operation are infection, bleeding, drug allergy, heart attack, DVT, pulmonary embolism, pneumonia, urinary tract infection, general anaesthesia and death.
Specific risks from the front are:
Blood transfusion is uncommon, and the need for this is reduced using the “Cell-Saver”, a machine used during the operation. Any blood loss from the patient is filtered and returned to the patient, thus minimising the risk of blood transfusion.
The discs in your spine act as shock absorbers, positioned between the blocks of bone called the vertebra. A disc comprises an outer wall of oblique fibres called the Annulus Fibrosus and an inner gel containing protein and water called the Nucleus Pulposus. The discs are flexible, allowing the spine to bend forward (flexion), backwards (extension), sideways (lateral flexion) and rotate.
Lumbar Total Disc Replacement (LTDR) is a type of surgical procedure that involves removing a damaged or diseased disc in the lower part of the spine (lumbar region) and replacing it with an artificial disc. This procedure aims to alleviate back pain while maintaining or restoring the natural motion of the spine.
An Artificial Disc is a device that can be implanted into the spine, replacing the damaged disc to permit normal load bearing and motion of the spine.
The Artificial Disc is also called a disc replacement, disc prosthesis or arthroplasty device. With total disc replacement, most of the disc tissue is removed, and the artificial disc is inserted into the disc space between the vertebrae.
Artificial Discs have two cobalt-chromium metal plates; one is attached to the vertebra above the disc being replaced and the other to the vertebra below. A central core, either metal or plastic (called polyethylene), is between the two plates, permitting motion in the ball and socket principal. The devices allow motion by smooth curved surfaces gliding across each other.
An LTDR is used in symptomatic disc degeneration with discogenic pain without significant facet joint disease.
Before the development of Artificial Discs, the only surgical option was fusion, where adjacent vertebral bodies were fused using interbody cages and bone after removing the damaged disc.
The goal of Artificial Disc replacement is to:
Artificial Disc replacement is usually performed in patients under 55 years of age.
Certain conditions prevent a patient from receiving an artificial disc. These include marked loss of disc space height, thin bones (osteoporosis), a slip of one vertebra across another (called spondylolisthesis), vertebral body fracture, spine tumour or infection, significant wear and tear arthritis in the small facet joints at the back of your spine or allergies to the materials in the artificial disc device. In addition, significant surgery to the front (anterior) of your neck or abdomen, previous radiotherapy or morbid obesity may prevent access to insert the artificial disc device into your neck or lumbar spine.
After removing the painful disc and relief of the spinal cord or nerve root compression, the Artificial Disc allows motion at the operated level.
In contrast to fusion, where the vertebrae above and below the damaged disc are fused, the Artificial Disc may reduce the wear and tear risks to discs above and below the operated level.
The Artificial Disc may permit a more rapid return to activities than fusion surgery.
The patient is encouraged to return to gradual progression and normal motion early in the postoperative period.
Tell Mr Malham about any medical conditions or previous operations. Suppose you have a medical condition such as diabetes, heart problems, high blood pressure or asthma. In that case, Mr Malham may arrange for a specialist physician to see you for a pre-operative assessment and medical care following the neurosurgery.
Inform Mr Malham of the medication you are taking and/or have allergies to medications. You must stop using the following ten days pre-operatively:
You must stop using blood thinning medication (such as Warfarin) 3-5 days pre-operatively.
Mr Malham is credentialed to use the Prestige, Prodisc-C, Mobi-C, Synergy, Maverick and M6 Lumbar prostheses. He has lectured, taught courses and attends regular national & international conferences on Artificial Disc Replacements.
Mr Malham’s preferred prostheses since 2004 are the Prestige and Synergy in the cervical or neck and Maverick with M6 in the lumbar region. This choice is based on the safety, stability (resistance to shear forces) and results these devices provide. All devices are TGA approved in Australia and FDA-approved in the U.S.A.
Mr Malham has no financial arrangement or benefits from using these prostheses.
The Lumbar Artificial Disc Replacement improves low back pain in 70 - 80% and lower limb pain in 80% of patients. No change in symptoms occurs in 10 - 20%.
The total risk of lumbar artificial disc replacement is 3 - 5%. Specific risks are bowel injury, ureter damage, bleeding from large retroperitoneal iliac arteries or veins, emboli (blood clots) to lower limbs and retrograde ejaculation in males.
General risks associated with any surgical procedure are heart attack, pneumonia, blood clots in the legs (DVT), which can travel to the lungs (pulmonary embolism), stroke, drug reaction, general anaesthesia and death.
If LTDR is delayed, it might result in prolonged discomfort and activity limitation due to chronic back pain. The degenerative process may continue and possibly worsen. However, delaying this surgery doesn't generally cause additional harm to the spine, assuming conservative measures are used to manage symptoms. As always, any decision related to the timing of surgery should be discussed with your surgeon, considering your specific condition and circumstances.
Contact Us
Hours
Monday to Friday
9.00am – 5.00pm
*This may vary on occasions or the rooms may be briefly unattended.
All Rights Reserved | Greg Malham, Neurosurgeon, BSc MBChB DMed FRACS